Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetrandrine plus GC chemotherapy for triple negative breast cancer
ChiCTR2000035314Phase 4Not yet recruiting
- Sponsor
- Beijing University of Chinese Medicine Fangshan Hospital
- Start
- Jun 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tetrandrine in triple-negative breast cancer (TNBC), sponsored by Beijing University of Chinese Medicine Fangshan Hospital. Primary endpoints: 12-lead electrocardiogram, Pregnancy test and 14 more. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
tetrandrine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2000035314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035314.